8-K: INmune Bio Provides Update on Clinical Programs and Pipeline

INmune Bio is advancing two novel platforms, XPro for Alzheimer's and INKmune for cancer, with key data readouts expected in the near term.

Summary

• INmune Bio is focused on developing treatments for inflammation and immunology, with two platforms in clinical trials: XPro and INKmune.
• XPro is being developed to treat Alzheimer's disease by targeting neuroinflammation, with Phase 2 top-line data expected in Q2 2025.
• The company is also planning to open a Phase 2 trial for Treatment Resistant Depression by the end of 2024.
• INKmune is designed to create memory-like NK cells to kill cancer, with an open-label Phase 1/2 trial for metastatic castrate-resistant prostate cancer ongoing.
• The company has a clean balance sheet with strong insider participation and ownership.
• XPro works by neutralizing soluble TNF (sTNF), which is believed to drive neuroinflammation and amyloid plaque deposition in Alzheimer's.
• Phase 1 studies of XPro have shown a reduction in CSF biomarkers of neuroinflammation and neurodegeneration, as well as improvements in synaptic function.
• The Phase 2 trial for XPro in early Alzheimer's is designed to be smaller and shorter, using the EMACC endpoint to measure cognitive change.
• INKmune aims to convert resting NK cells into cancer-killing memory-like NK cells, addressing the lack of T-cell infiltrate in prostate cancer.
• The Phase 1/2 trial for INKmune in metastatic castrate-resistant prostate cancer is ongoing, with data readouts expected.

Sentiment

Score: 7

Explanation: The document presents a positive outlook on the company's clinical programs and pipeline, with promising early results and clear milestones. However, it also acknowledges the risks associated with drug development and the need for future capital raises.

Positives

• XPro has shown promising results in Phase 1 trials, including reductions in neuroinflammation and neurodegeneration biomarkers.
• XPro has demonstrated improvements in synaptic function in Phase 1 trials.
• The Phase 2 Alzheimer's trial is designed to be smaller and shorter, using the EMACC endpoint for precise cognitive measurement.
• INKmune has shown no reported toxicity to date.
• INKmune targets the immune cells most prominent in the tumor microenvironment of prostate cancer.
• The company has a clean balance sheet with strong insider participation and ownership.

Negatives

• The company is still in the clinical trial phase, and there is no guarantee of success.
• The company is reliant on raising capital to fund continuing operations.
• There is competition from other providers and products in the market.
• The company is subject to risks related to intellectual property protection and potential litigation.

Risks

• The company's ability to raise capital to fund continuing operations is a risk.
• The company faces competition from other providers and products.
• There are risks associated with protecting intellectual property rights.
• The company could face litigation or infringement actions.
• Changes in government regulations could impact the company's operations.
• The company's ability to develop and commercialize products and services is not guaranteed.
• There is no guarantee that any specific outcome will be achieved in clinical trials.

Future Outlook

The company anticipates top-line Phase 2 Alzheimer's data in Q2 2025, an end-of-Phase 2 FDA meeting in Q3 2025, and the initiation of a Phase 2 Treatment Resistant Depression trial in 2H 2024. They also expect to complete Phase 2 mCRPC enrollment in 1H 2025 and have ongoing open-label Phase 2 mCRPC data.

Management Comments

• The company intends to use the provided slide deck in presentations from time to time.
• Management believes that XPro targets the most important pathology in Alzheimer's, which is neuroinflammation.
• Management aims to use a modern precision medicine clinical trial design to derisk the clinical program.

Industry Context

The company is operating in the competitive fields of Alzheimer's and cancer therapeutics, where there is a high unmet need for effective treatments. The approach of targeting neuroinflammation in Alzheimer's and using NK cell therapy in cancer represents novel strategies.

Comparison to Industry Standards

• Current TNF inhibitors are contraindicated for neurological diseases, while XPro is designed to be safe for the brain by selectively inhibiting soluble TNF.
• The company is using the EMACC endpoint in its Phase 2 Alzheimer's trial, which is designed to be more sensitive to cognitive changes than traditional measures like CDR.
• The company's approach to prostate cancer treatment with INKmune differs from traditional immune checkpoint inhibitors, which have not been effective in mCRPC.
• The company's INKmune approach is designed to convert resting NK cells into cancer-killing memory-like NK cells, which is a novel approach compared to cytokine-primed NK cells.

Stakeholder Impact

• Shareholders may be impacted by the clinical trial results and the company's ability to raise capital.
• Employees are impacted by the company's progress in clinical trials and the overall success of the company.
• Patients with Alzheimer's and prostate cancer may benefit from the company's therapies if they are successful.
• The company's suppliers and creditors are impacted by the company's financial health and ability to operate.

Next Steps

• The company will continue to enroll patients in the Phase 2 Alzheimer's trial.
• The company will initiate a Phase 2 trial for Treatment Resistant Depression.
• The company will continue to enroll patients in the Phase 1/2 mCRPC trial.
• The company will provide top-line data from the Phase 2 Alzheimer's trial in Q2 2025.
• The company will have an end-of-Phase 2 FDA meeting for Alzheimer's in Q3 2025.

Key Dates

Keywords

Alzheimer's disease, prostate cancer, XPro, INKmune, neuroinflammation, NK cells, clinical trials, immunology, inflammation, sTNF, mCRPC, EMACC